Assembly Biosciences (NASDAQ: ASMB) is one of 19 public companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Assembly Biosciences to similar businesses based on the strength of its analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Assembly Biosciences and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Assembly Biosciences 0 0 1 0 3.00
Assembly Biosciences Competitors 99 377 981 28 2.63

Assembly Biosciences presently has a consensus price target of $35.00, suggesting a potential upside of 0.23%. As a group, “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 19.17%. Given Assembly Biosciences’ competitors higher possible upside, analysts clearly believe Assembly Biosciences has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

72.3% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 66.4% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by institutional investors. 19.6% of Assembly Biosciences shares are owned by company insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Assembly Biosciences has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Assembly Biosciences’ competitors have a beta of 0.81, suggesting that their average stock price is 19% less volatile than the S&P 500.

Valuation and Earnings

This table compares Assembly Biosciences and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Assembly Biosciences $3.04 million -$50.92 million -12.74
Assembly Biosciences Competitors $2.57 billion $977.16 million 0.77

Assembly Biosciences’ competitors have higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Assembly Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Assembly Biosciences N/A -68.83% -43.63%
Assembly Biosciences Competitors -541.18% -46.12% -27.91%

Summary

Assembly Biosciences competitors beat Assembly Biosciences on 7 of the 12 factors compared.

About Assembly Biosciences

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.

Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.